Cargando…
Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
BACKGROUND: The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) – supposed to be involved in protection of cells from apoptosis and oxidative stress – has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533746/ https://www.ncbi.nlm.nih.gov/pubmed/22978347 http://dx.doi.org/10.1186/1476-4598-11-69 |
_version_ | 1782254447297036288 |
---|---|
author | Aust, Stefanie Bachmayr-Heyda, Anna Pateisky, Petra Tong, Dan Darb-Esfahani, Silvia Denkert, Carsten Chekerov, Radoslav Sehouli, Jalid Mahner, Sven Van Gorp, Toon Vergote, Ignace Speiser, Paul Horvat, Reinhard Zeillinger, Robert Pils, Dietmar |
author_facet | Aust, Stefanie Bachmayr-Heyda, Anna Pateisky, Petra Tong, Dan Darb-Esfahani, Silvia Denkert, Carsten Chekerov, Radoslav Sehouli, Jalid Mahner, Sven Van Gorp, Toon Vergote, Ignace Speiser, Paul Horvat, Reinhard Zeillinger, Robert Pils, Dietmar |
author_sort | Aust, Stefanie |
collection | PubMed |
description | BACKGROUND: The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) – supposed to be involved in protection of cells from apoptosis and oxidative stress – has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor α (ERα) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ERα expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ERα in regard to clinicopathological parameters, chemotherapy response, and survival. METHODS AND RESULTS: Expressions of TRAP1 and ERα were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ERα was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ERα (p < 0.001) but high TRAP1 expression was also found in 42% of ERα negative cases. High TRAP1 expression correlated significantly with favorable chemotherapy-response (HR = 0.48; 95%CI 0.24-0.96, p=0.037) and showed a significant impact on overall survival (OS) (HR = 0.65; 95%CI 0.43-0.99, p = 0.044). ERα expression was a favorable prognostic factor for OS in univariate and multivariate analyses. Interestingly, the combined pattern (ERα positive and/or TRAP1-high) revealed the strongest independent and significant positive influence on OS (HR = 0.41; 95%CI 0.27-0.64). CONCLUSION: Immunohistochemical evaluation of TRAP1 together with ERα provides significant prognostic information. TRAP1 alone is significantly associated with chemotherapy response and overall survival, rendering TRAP1 as interesting scientific and therapeutic target. |
format | Online Article Text |
id | pubmed-3533746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35337462013-01-03 Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium Aust, Stefanie Bachmayr-Heyda, Anna Pateisky, Petra Tong, Dan Darb-Esfahani, Silvia Denkert, Carsten Chekerov, Radoslav Sehouli, Jalid Mahner, Sven Van Gorp, Toon Vergote, Ignace Speiser, Paul Horvat, Reinhard Zeillinger, Robert Pils, Dietmar Mol Cancer Research BACKGROUND: The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) – supposed to be involved in protection of cells from apoptosis and oxidative stress – has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor α (ERα) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ERα expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ERα in regard to clinicopathological parameters, chemotherapy response, and survival. METHODS AND RESULTS: Expressions of TRAP1 and ERα were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ERα was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ERα (p < 0.001) but high TRAP1 expression was also found in 42% of ERα negative cases. High TRAP1 expression correlated significantly with favorable chemotherapy-response (HR = 0.48; 95%CI 0.24-0.96, p=0.037) and showed a significant impact on overall survival (OS) (HR = 0.65; 95%CI 0.43-0.99, p = 0.044). ERα expression was a favorable prognostic factor for OS in univariate and multivariate analyses. Interestingly, the combined pattern (ERα positive and/or TRAP1-high) revealed the strongest independent and significant positive influence on OS (HR = 0.41; 95%CI 0.27-0.64). CONCLUSION: Immunohistochemical evaluation of TRAP1 together with ERα provides significant prognostic information. TRAP1 alone is significantly associated with chemotherapy response and overall survival, rendering TRAP1 as interesting scientific and therapeutic target. BioMed Central 2012-09-14 /pmc/articles/PMC3533746/ /pubmed/22978347 http://dx.doi.org/10.1186/1476-4598-11-69 Text en Copyright ©2012 Aust et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Aust, Stefanie Bachmayr-Heyda, Anna Pateisky, Petra Tong, Dan Darb-Esfahani, Silvia Denkert, Carsten Chekerov, Radoslav Sehouli, Jalid Mahner, Sven Van Gorp, Toon Vergote, Ignace Speiser, Paul Horvat, Reinhard Zeillinger, Robert Pils, Dietmar Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium |
title | Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium |
title_full | Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium |
title_fullStr | Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium |
title_full_unstemmed | Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium |
title_short | Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium |
title_sort | role of trap1 and estrogen receptor alpha in patients with ovarian cancer -a study of the ovcad consortium |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533746/ https://www.ncbi.nlm.nih.gov/pubmed/22978347 http://dx.doi.org/10.1186/1476-4598-11-69 |
work_keys_str_mv | AT auststefanie roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT bachmayrheydaanna roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT pateiskypetra roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT tongdan roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT darbesfahanisilvia roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT denkertcarsten roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT chekerovradoslav roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT sehoulijalid roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT mahnersven roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT vangorptoon roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT vergoteignace roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT speiserpaul roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT horvatreinhard roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT zeillingerrobert roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium AT pilsdietmar roleoftrap1andestrogenreceptoralphainpatientswithovariancancerastudyoftheovcadconsortium |